HomeCompareKYKOF vs EPRT

KYKOF vs EPRT: Dividend Comparison 2026

KYKOF yields 3.62% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KYKOF wins by $15.6K in total portfolio value· pulled ahead in Year 4
10 years
KYKOF
KYKOF
● Live price
3.62%
Share price
$12.42
Annual div
$0.45
5Y div CAGR
34.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.9K
Annual income
$20,662.92
Full KYKOF calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — KYKOF vs EPRT

📍 KYKOF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKYKOFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KYKOF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KYKOF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KYKOF
Annual income on $10K today (after 15% tax)
$307.97/yr
After 10yr DRIP, annual income (after tax)
$17,563.48/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, KYKOF beats the other by $6,368.26/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KYKOF + EPRT for your $10,000?

KYKOF: 50%EPRT: 50%
100% EPRT50/50100% KYKOF
Portfolio after 10yr
$72.1K
Annual income
$16,916.89/yr
Blended yield
23.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

KYKOF
No analyst data
Altman Z
4.5
Piotroski
6/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KYKOF buys
0
EPRT buys
0
PoliticianChamberTickerTypeAmountDate
Daniel Goldman🏢 House$EPRT▼ Sell$15,001 - $50,0002023-07-12
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKYKOFEPRT
Forward yield3.62%3.97%
Annual dividend / share$0.45$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR34.2%29%
Portfolio after 10y$79.9K$64.3K
Annual income after 10y$20,662.92$13,170.85
Total dividends collected$53.3K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: KYKOF vs EPRT ($10,000, DRIP)

YearKYKOF PortfolioKYKOF Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,186$486.23$11,212$512.01$26.00EPRT
2$12,651$682.18$12,689$692.09$38.00EPRT
3$14,505$967.66$14,521$944.30$16.00EPRT
4← crossover$16,911$1,391.42$16,841$1,302.88+$70.00KYKOF
5$20,130$2,034.69$19,841$1,821.64+$289.00KYKOF
6$24,577$3,037.59$23,818$2,587.47+$759.00KYKOF
7$30,948$4,651.34$29,230$3,744.65+$1.7KKYKOF
8$40,461$7,346.19$36,816$5,540.38+$3.6KKYKOF
9$55,339$12,045.62$47,806$8,413.17+$7.5KKYKOF
10$79,875$20,662.92$64,324$13,170.85+$15.6KKYKOF

KYKOF vs EPRT: Complete Analysis 2026

KYKOFStock

Kyowa Kirin Co., Ltd. manufactures and markets pharmaceuticals that focuses on the therapeutic areas of oncology, nephrology, central nervous system, and immunology worldwide. Its products include ABSTRAL, a sublingual formulation of fentanyl used for the management of episodes of breakthrough pain experienced by cancer patients; ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. In addition, it offers PecFent, a nasally administrated spray; POTELIGEO, a humanized monoclonal antibody for CC chemokine receptor 4; REGPARA for the treatment of secondary hyperparathyroidism; Romiplate/Nplate, a genetically recombinant protein for platelet production of thrombopoietin receptors; and SANCUSO for the treatment of nausea and vomiting. Kyowa Kirin Co., Ltd. has an agreement with Amgen Inc. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in June 2019. The company was incorporated in 1949 and is headquartered in Tokyo, Japan. Kyowa Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

Full KYKOF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this KYKOF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KYKOF vs SCHDKYKOF vs JEPIKYKOF vs OKYKOF vs KOKYKOF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.